Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells

B. Ziccheddu; C. Savid-Frontera; V. V. G. Saralamma; C. Gatenbee; A. A. Youssfi; M. Chojnacka; M. Menges; L. Cuadrado-Delgado; M. Durante; J. Mullinax; K. Reid; J. A. Miranda; S. Corallo; E. Merritt; W. Sawyer; A. Augello; A. D. Newsam; D. Chahar; C. Amador; J. Y. Spiegel; M. Davila; O. Landgren; J. P. Alderuccio; M. Robertson-Tessi; R. Atkins; S. Usmani; M. D. Jain; A. R. A. Anderson; F. Maura; J. H. Schatz; F. L. Locke

doi:10.64898/2026.10.23.761341

AI summary · DOI: 10.64898/2026.10.23.761341 · bioRxiv: Cancer Biology

Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells

B. Ziccheddu, C. Savid-Frontera, V. V. G. Saralamma, C. Gatenbee, A. A. Youssfi, M. Chojnacka, M. Menges, L. Cuadrado-Delgado,

and 23 more authors

M. Durante, J. Mullinax, K. Reid, J. A. Miranda, S. Corallo, E. Merritt, W. Sawyer, A. Augello, A. D. Newsam, D. Chahar, C. Amador, J. Y. Spiegel, M. Davila, O. Landgren, J. P. Alderuccio, M. Robertson-Tessi, R. Atkins, S. Usmani, M. D. Jain, A. R. A. Anderson, F. Maura, J. H. Schatz, F. L. Locke

How to read this summary? Illustrated guide

The essentials

The study finds that durable CAR-T responses in large B-cell lymphoma depend on cooperation between CAR-T cells and endogenous CD8 T cells.

Based on the abstract only: check the details in the original paper.

Question

Why do some patients with relapsed or refractory large B-cell lymphoma achieve durable responses to CD19-directed CAR-T therapy while others do not? The study examines whether endogenous tumor-reactive CD8 T cells contribute to treatment efficacy.

Method

The authors integrated whole-genome and transcriptome profiling from 54 patients with functional assays, syngeneic models, and mathematical modeling. They also tested tumor responses in immunocompetent mice, including experiments with CD8-cell depletion, and assessed endogenous T-cell activation using patient data and murine ELISPOT assays.

Findings

Result Tumors with biallelic loss of MHC class I or CD58 had greater genomic complexity, higher neoantigen burden, and resistance to CAR-T therapy.
See the passage in the paper
Tumors with biallelic loss of MHC class I or CD58 exhibited high genomic complexity, increased neoantigen burden, and resistance to CAR-T therapy.
Result MHC-I-deficient lymphomas responded less well to CAR-T therapy in immunocompetent hosts than wild-type lymphomas.
See the passage in the paper
MHC-I-deficient lymphomas showed suboptimal response in immunocompetent hosts compared to wild type.
Result In mice, sustained responses required endogenous CD8 cells; all CD8-depleted mice relapsed after initial tumor regression induced by CAR-T cells.
See the passage in the paper
Importantly, sustained responses in mice occurred only in the presence of eCD8 cells, whereas all CD8-depleted mice relapsed after initial CAR-T-mediated tumor regression.
Result The patient and mouse findings support increased activation of endogenous T cells after CAR-T therapy.
See the passage in the paper
Patients and murine ELISPOT assays confirmed enhanced endogenous T-cell activation post-CAR-T.
Authors’ interpretation The authors interpret CAR-T therapy as a catalyst for endogenous antitumor immunity, rather than solely a direct cytotoxic treatment.
See the passage in the paper
These findings reveal that CAR-T therapy functions not only as a cytotoxic modality but also as a catalyst for endogenous anti-tumor immunity.

Limitations

The abstract does not specify limitations; the reported patient profiling covers 54 patients, so the evidence described is limited to that cohort and the accompanying models.

Why it matters

The authors argue that durable CAR-T efficacy involves cooperation between engineered CAR-T cells and endogenous CD8 T cells. This frames endogenous antitumor immunity as a contributor to treatment response and highlights tumor MHC-I and CD58 loss as features associated with resistance.

Written by AI from the paper. Passages are checked word for word against the text we analysed; the rest may contain errors.

AI-generated keywords: CAR-T therapy CD19 CD8 T cells large B-cell lymphoma tumor immune evasion

Read further

Comprehensive Summary
Layman's Summary
Blog article
Original abstract

The paper asks why CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy produces durable remissions in some patients with relapsed or refractory large B-cell lymphoma but fails in others or is followed by relapse. Its central conclusion is that CAR-T cells may rely on the patient’s own tumor-reactive CD8 T cells to sustain treatment responses. The authors present CAR-T therapy not only as a direct attack on lymphoma cells, but also as a potential trigger for a broader, endogenous anti-tumor immune response. The study combined genomic and transcriptomic profiling of tumors from 54 patients with functional experiments, syngeneic mouse models, and mathematical modeling. The researchers examined tumor features such as loss of MHC class I and CD58 and investigated whether endogenous CD8 T cells became activated after CAR-T treatment. The abstract does not provide further details about the experimental protocols, patient characteristics, or mathematical model. The authors report that durable CAR-T efficacy depended on cooperation between CAR-T cells and endogenous CD8 T cells that attack malignant cells. Tumors with biallelic loss of either MHC class I or CD58 had greater genomic complexity and higher neoantigen burden, and were associated with CAR-T resistance. In immunocompetent mice, lymphomas lacking MHC class I responded less well than wild-type tumors. Depleting CD8 T cells provided further evidence of their role: CAR-T treatment initially reduced tumor burden, but every CD8-depleted mouse relapsed. In contrast, sustained responses in the mouse experiments occurred only when endogenous CD8 T cells were present. The abstract does not report group sizes, response percentages beyond this finding, follow-up durations, or statistical estimates. Evidence of endogenous T-cell activation came from both patients and mice. Patient observations and murine ELISPOT assays showed enhanced endogenous T-cell activation after CAR-T therapy. These findings support the proposed model that CAR-T treatment can recruit or stimulate the host’s anti-tumor immunity, which then helps maintain tumor control. However, the abstract does not specify how many patient samples showed this activation, the magnitude of the changes, or the precise assays and timing. Overall, the authors conclude that endogenous tumor-reactive CD8 T cells are important partners in durable CAR-T responses, while tumor immune-evasion features such as MHC class I or CD58 loss may limit this cooperation. Assessing tumor genetics and host immune activity could help explain differences in outcomes and inform future research into strategies for improving therapy. These are implications for further study, not clinical recommendations established by the abstract. Only the title, authors, and abstract were available; the paper’s license does not permit access to the full text. As a result, this summary cannot assess the detailed methods, the strength and uncertainty of the statistical evidence, patient-level outcomes, or the authors’ full discussion of limitations. The abstract also does not report a clinical intervention showing that boosting endogenous CD8 T cells improves patient outcomes. The findings support a mechanistic conclusion, but the available information is insufficient to determine how broadly it applies across patients or lymphoma subtypes.

Why Some Lymphomas Stay Gone After CAR-T Therapy

CD19-directed CAR-T therapy can produce lasting remissions for people with relapsed or refractory large B-cell lymphoma. But not everyone benefits: some tumors resist treatment, and others return after an initial response. Why these outcomes differ remains an important question.

In “Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells,” B. Ziccheddu, C. Savid-Frontera, V. V. G. Saralamma, C. Gatenbee, A. A. Youssfi, M. Chojnacka et al. investigate a possible answer. Their central idea is that CAR-T cells may need help from the patient’s own tumor-reactive CD8 T cells to keep lymphoma under control. In this view, CAR-T treatment is not only a direct attack on cancer cells; it may also help activate a wider immune response.

A Two-Part Immune Attack

CAR-T cells are engineered to recognize a target on cancer cells—in this case, CD19. The researchers propose that this targeted attack may work together with endogenous CD8 T cells: immune cells already present in the patient that can recognize and kill malignant cells. If CAR-T treatment helps these native T cells become active, they might continue fighting the cancer and help sustain a remission.

To explore this possibility, the study combined genomic and transcriptomic profiling of tumors from 54 patients with functional experiments, mouse models, and mathematical modeling. The researchers examined tumor features that could affect immune recognition, including loss of MHC class I and CD58, and looked for signs that endogenous CD8 T cells became activated after treatment.

Tumor Changes Linked to Resistance

The authors report that tumors with biallelic loss of either MHC class I or CD58 had greater genomic complexity and a higher neoantigen burden. These features were associated with resistance to CAR-T therapy. MHC class I is relevant because it helps display pieces of a cell’s contents to T cells, while CD58 is involved in communication between immune cells. Losing either feature could make it harder for the patient’s own T cells to recognize or respond to lymphoma.

The mouse experiments offered functional evidence for the importance of this immune partnership. In immunocompetent mice, lymphomas lacking MHC class I responded less well to CAR-T treatment than wild-type tumors. When researchers depleted CD8 T cells, treatment initially reduced tumor burden, but every CD8-depleted mouse relapsed. Sustained responses in these experiments occurred only when endogenous CD8 T cells were present.

Signs That the Host Immune System Joins In

The study also reports evidence of endogenous T-cell activation after CAR-T treatment. Patient observations and murine ELISPOT assays showed enhanced activation, supporting the possibility that CAR-T cells can recruit or stimulate the host’s own anti-tumor immunity. That response, in turn, may help maintain control of the cancer after the initial CAR-T attack.

The available abstract does not specify how many patient samples showed increased activation, how large the changes were, or exactly when and how the measurements were made. It therefore supports the proposed mechanism without allowing a detailed assessment of its strength in patients.

What the Findings May Mean

Taken together, the results point to a more collaborative picture of CAR-T therapy. Treatment may depend not only on engineered cells recognizing lymphoma, but also on whether the patient’s immune system can contribute to the fight. Tumor changes that interfere with immune recognition may weaken that cooperation and help explain why some cancers resist treatment or return.

The work suggests that studying both tumor genetics and host immune activity could help researchers understand differences in response. It may also guide future research into ways of improving CAR-T therapy. These are research implications, not established clinical recommendations: the abstract does not report a clinical intervention showing that boosting endogenous CD8 T cells improves outcomes.

What We Still Don’t Know

This summary is based only on the paper’s title, author list, and abstract; the full text was not available. The abstract does not provide detailed protocols, patient characteristics, group sizes, follow-up periods, or statistical estimates. It also does not allow assessment of patient-level outcomes, the uncertainty around the results, or the authors’ full discussion of limitations.

The findings support a mechanistic conclusion: endogenous tumor-reactive CD8 T cells appear to be important partners in durable CAR-T responses, while features such as MHC class I or CD58 loss may limit that cooperation. Further work will be needed to determine how broadly this model applies across patients and lymphoma subtypes, and whether acting on it can improve clinical outcomes.

Created on 02 Nov. 2026

Was this synthesis useful?

Score: 0

Ask questions about this paper to our AI assistant

How to chat with this paper? Illustrated guide

You can also chat with multiple papers at once here.

⚠The license of the paper does not allow us to build upon its content and the AI assistant only knows about the paper metadata rather than the full article.

AI assistant instructions?

Tools for this paper

Explain it differently 3 free rewrites left today

Save to a collection Group papers in collections to compare them, chat with them and export them. Create a free account Log in

Export BibTeX · RIS (Zotero, Mendeley, EndNote) · Obsidian (Markdown) · Notion (Markdown)

Advanced tools Premium

For researchers who follow a field closely: citation alerts, journal-club slides, version comparison and Zotero export. Discover Premium

Zotero

Citation alerts Citation alerts guide

Who works on it? The people and institutions who publish on its topic

Weekly letter Presented in "Biology and medicine this week" of 2 November 2026. Biology and medicine this week: Hidden partners, adjustable gates and overlooked disease

Journal club Premium+ Slides to present it Propose for the journal club

Talk about it in public Premium+ Press kit: release, questions, hype check Press kit guide

Papers around this one

See them on a map

Ranked by how close their title and abstract are to this paper’s. Select some to read them together.

Closest papers

Very close Review
CAR T cell cancer immunotherapy: who does the job?
D. Harrer, Markus Barden, H. Abken · 2026 · Frontiers in Immunology · Not summarized yet

“CAR T cell cancer immunotherapy: who does the job?” reviews how endogenous adaptive and innate immune cells contribute to CAR-T outcomes.

Abstract
Chimeric antigen receptor (CAR) T cells are capable to eliminate cancer cells in the treatment of hematologic malignancies, yet the efficacy is frequently inconsistent and limited by cancer cell resistance and antigen-loss resulting in early tumor relapses. While CAR T cells are deemed to be the primary effectors in controlling the tumor, maturing evidence indicates that therapeutic outcomes are shaped by a broader immune cell network involving both the endogenous adaptive and innate immunity. In this review, we reframe CAR T cell therapy as the induction of a multi-system immune response rather than a uni-directional cytotoxic cell-autonomous intervention. We discuss the respective contribu…
Very close Same question
CD8 T-cell exhaustion linked with CAR T-cell failure can be mitigated by a non-alpha IL2 receptor agonist.
Kotaro Arita, En-Yu Dai, Xu-Bin Li et al. · 2026 · Blood · Not summarized yet

“CD8 T-cell exhaustion linked with CAR T-cell failure” studies immune mechanisms of CART19 failure in relapsed or refractory large B-cell lymphoma, focusing on CAR-T cell exhaustion.

Abstract
Chimeric antigen receptor T-cell (CART19) therapy represents a breakthrough for relapsed or refractory large B-cell lymphoma (rrLBCL). However, suboptimal CART19 activity can lead to therapeutic failure and dismal outcomes. Through single cell RNA-sequencing of tumors at the time of progression from CART19, we show that a subset of tumor contain clonally expanded and proliferating populations of CART19 cells that acquire transcriptional features of dysfunction, suggestive of ongoing tumor cell engagement and chronic stimulation. Using an in vitro system to model this process, we show that iterative rechallenge of CART19 cells with target cells drives failure of tumor control associated with …
Very close Another approach to the problem
Model-based integration of chimeric antigen receptor T-cell kinetics and tumor features to predict therapeutic outcomes in patients with B-cell malignancies
Jonas Schadt, M. Rohnert, Paul Matthiensen et al. · 2026 · Frontiers in Immunology · Not summarized yet

“Model-based integration” predicts outcomes in B-cell malignancies by combining CAR-T kinetics and tumor features in a mechanistic model.

Abstract
Introduction Chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for several hematological malignancies, yet patient-specific responses and toxicities remain hard to predict. Although multiple covariates and risk scores exist, their prognostic accuracy remains limited. Methods We prospectively measured CAR T-cell kinetics in peripheral blood of 92 patients with B-cell malignancies using multicolor flow cytometry. To explore underlying mechanisms, we developed a mechanistic model of CAR T-cell and tumor cell interactions. Results We captured four phases of CAR T-cell kinetics in peripheral blood: distribution, expansion, contraction, and persistence. Patients with weak expa…
Very close Review
Clinical and Biological Correlates of Resistance and Relapse After CD19-Directed CAR T-Cell Therapy in Large B-Cell Lymphoma: A Structured Narrative Review
Jean Silva de Souza Resende, I. S. Giner, Maria Gabriela Custodio de Figueiredo et al. · 2026 · Cancers · Not summarized yet

“Clinical and Biological Correlates” reviews clinical and biological factors associated with resistance and relapse after CD19-directed CAR-T therapy in large B-cell lymphoma.

Abstract
Simple Summary CD19-directed chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of large B-cell lymphoma (LBCL), but many patients either do not respond or subsequently relapse. This structured narrative review examines clinical outcomes and biological factors associated with resistance and relapse. Across 14 studies, treatment failure could not be attributed to loss of CD19 alone, although incomplete assessment of CD19 at relapse limits this interpretation. Tumor-intrinsic programs, impaired CAR T-cell fitness and persistence, systemic inflammation, and an immunosuppressive tumor microenvironment also contributed, although differences in study design and incomplete…
Very close Broader context
T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?
Federico Stella, J. Fraietta, S. Schuster et al. · 2026 · Haematologica · Not summarized yet

“T-cell lymphoma following chimeric antigen receptor-T therapy” reviews rare secondary T-cell lymphomas as a long-term safety concern after CAR-T treatment.

Abstract
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory B-cell malignancies and multiple myeloma, with tens of thousands of patients treated worldwide. As survival improves, long-term safety has come into focus, and rare reports of T-cell lymphomas occurring after CAR T-cell infusion have prompted regulatory scrutiny and heightened clinical attention. Drawing on pivotal trials, real-world registries, meta-analyses, pharmacovigilance data, and detailed molecular case reports, we review the incidence, biological plausibility, and clinical relevance of lymphomas arising after CAR T-cell therapy. Registry data and large institutional series consi…
Very close Review
Relapse and progression after CAR-T cell therapy in large B-cell lymphoma: Patterns, mechanisms, and salvage strategies.
Ling-Zhi Wang, Qing Li, Xiao-Jian Zhu · 2026 · Cancer Treatment and Research Communications · Not summarized yet

“Relapse and progression after CAR-T cell therapy” reviews relapse patterns, mechanisms, risk factors, and salvage strategies in large B-cell lymphoma.

Abstract
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for large B-cell lymphoma (LBCL), particularly in the relapsed or refractory. However, relapse after CAR-T cell therapy remains a major barrier to durable remission and long-term survival because post-CAR-T relapse is biologically and clinically heterogeneous and lacks standardized management strategies. In this narrative review, we provide a clinically oriented synthesis of the current evidence on relapse or progression after CAR-T cell therapy in LBCL, focusing on relapse patterns, underlying biological mechanisms, risk factors, and evolving salvage strategies. Evidence from other B-cell lymphoma subtype…
Very close Broader context
Targeting Peripheral T-Cell Lymphomas with Chimeric Antigen Receptor Therapy: Mechanistic Challenges, Clinical Landscape and Future Engineering Perspectives
R. Irimia, P. Piccaluga · 2026 · Cancers · Not summarized yet

“Targeting Peripheral T-Cell Lymphomas” reviews CAR therapy challenges in T-cell lymphoma, a different cancer from the B-cell lymphoma studied here.

Abstract
Simple Summary Peripheral T-cell lymphomas are aggressive forms of cancers caused by mature T lymphocytes. These cancers respond poorly to standard chemotherapy, leaving a pressing need for new treatments. Chimeric antigen receptor (CAR) cell therapy, which reprograms immune cells to recognize and kill tumor cells, has transformed the treatment of B-cell cancers, but its use against T-cell tumors has been held back by problems unique to T-cell lineage: the engineered cells tend to attack one another, healthy T-cells can be destroyed alongside the cancer, and tumor cells can contaminate the therapeutic product. This review summarizes how newer engineering strategies address these obstacles, e…
Very close Broader context
Targeting the tumor, harboring the host: IL-7 receptor-targeted CARs to treat T-ALL
V. Kuznetsova, Rishi K. Kothuru, P. Adusumilli et al. · 2026 · Molecular therapy. Oncology · Not summarized yet

“Targeting the tumor, harboring the host” discusses IL-7 receptor-targeted CARs for T-ALL and the fratricide problem caused by shared antigens.

Abstract
Chimeric antigen receptor (CAR) T cell therapy has fundamentally transformed clinical outcomes in B cell malignancies; however, the success story of CAR T cells has not yet extended to T cell acute lymphoblastic leukemia (T-ALL). A primary issue lies in the fundamental biology of the disease; most target antigens are shared be-tween malignant T-ALL blasts and healthy T lymphocytes, including the CAR T cell product itself. This overlap triggers fratricide, a unique on-target, off-tumor toxicity in which CAR T cells recognize and destroy each other as well as bystander normal T cells. This self-destruction compromises the manufacturing yield, impairs in vivo persistence, and introduces the ris…

Go further

How are these papers found?

We compare the title and abstract of this paper with those of every paper summarized on this site, and with the papers Semantic Scholar recommends, those it cites and those citing it (for a much-cited paper, its most recent citations and, from OpenAlex, the most cited ones). Among the prior work and the follow-ups, the papers that use each other in depth, a method it uses and the much-cited follow-ups come a little higher. The levels (very close, close, related) come from the similarity of the texts, not from a judgment of quality; * marks a paper without an abstract, compared by its title. The sentence under a paper is written by an AI from the two abstracts: check it in the papers. A paper marked not relevant by three readers leaves the list.

Updated on 2 November 2026.

Disclaimer: The AI-based summarization tool and virtual assistant provided on this website may not always provide accurate and complete summaries or responses. We encourage you to carefully review and evaluate the generated content to ensure its quality and relevance to your needs.

Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells

The essentials

Question

Method

Findings

Limitations

Why it matters

Read further

Definitions

Why Some Lymphomas Stay Gone After CAR-T Therapy

A Two-Part Immune Attack

Tumor Changes Linked to Resistance

Signs That the Host Immune System Joins In

What the Findings May Mean

What We Still Don’t Know

Ask questions about this paper to our AI assistant

Tools for this paper

Advanced tools Premium

Papers around this one

Closest papers

Go further

Cite this paper (BibTeX)